In the phase 3 COMPETE trial of 309 patients with advanced progressive GEP NETs, [177Lu]Lu-edotreotide vs everolimus gave longer median progression-free survival (23.9 vs 14.1 months; HR 0.67), with fewer grade 3-4 treatment-related adverse events (18% vs 40%).
RCTn = 309
Walter et al. [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial